138 related articles for article (PubMed ID: 10930109)
1. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy.
Ottesen GL; Christensen IJ; Larsen JK; Larsen J; Baldetorp B; Linden T; Hansen B; Andersen J
Breast Cancer Res Treat; 2000 Apr; 60(3):219-26. PubMed ID: 10930109
[TBL] [Abstract][Full Text] [Related]
2. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
3. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
Leal CB; Schmitt FC; Bento MJ; Maia NC; Lopes CS
Cancer; 1995 Apr; 75(8):2123-31. PubMed ID: 7697603
[TBL] [Abstract][Full Text] [Related]
4. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.
Rudas M; Neumayer R; Gnant MF; Mittelböck M; Jakesz R; Reiner A
Eur J Cancer; 1997 Jan; 33(1):39-44. PubMed ID: 9071897
[TBL] [Abstract][Full Text] [Related]
5. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
6. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast.
Buerger H; Simon R; Schäfer KL; Diallo R; Littmann R; Poremba C; van Diest PJ; Dockhorn-Dworniczak B; Böcker W
Mol Pathol; 2000 Jun; 53(3):118-21. PubMed ID: 10897329
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous expression of nm23 gene product in noninvasive breast carcinoma.
Simpson JF; O'Malley F; Dupont WD; Page DL
Cancer; 1994 May; 73(9):2352-8. PubMed ID: 7513249
[TBL] [Abstract][Full Text] [Related]
8. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
9. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases.
Sneige N; Wang J; Baker BA; Krishnamurthy S; Middleton LP
Mod Pathol; 2002 Oct; 15(10):1044-50. PubMed ID: 12379750
[TBL] [Abstract][Full Text] [Related]
10. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
11. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions.
Andrade VP; Ostrovnaya I; Seshan VE; Morrogh M; Giri D; Olvera N; De Brot M; Morrow M; Begg CB; King TA
Breast Cancer Res; 2012 Jul; 14(4):R103. PubMed ID: 22776144
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
[TBL] [Abstract][Full Text] [Related]
13. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.
Ottesen GL; Graversen HP; Blichert-Toft M; Christensen IJ; Andersen JA
Breast Cancer Res Treat; 2000 Aug; 62(3):197-210. PubMed ID: 11072784
[TBL] [Abstract][Full Text] [Related]
14. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric DNA analysis of breast cancers with predominance of carcinoma in situ: a comparison of the premalignant and malignant components.
Ottesen GL; Christensen IJ; Larsen JK; Hansen B; Andersen AJ
Clin Cancer Res; 1995 Aug; 1(8):881-8. PubMed ID: 9816058
[TBL] [Abstract][Full Text] [Related]
16. Molecular evolutionary patterns in breast cancer.
Shackney SE; Silverman JF
Adv Anat Pathol; 2003 Sep; 10(5):278-90. PubMed ID: 12973049
[TBL] [Abstract][Full Text] [Related]
17. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.
Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH
Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530
[TBL] [Abstract][Full Text] [Related]
18. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
19. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
[TBL] [Abstract][Full Text] [Related]
20. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
Albonico G; Querzoli P; Ferretti S; Rinaldi R; Nenci I
Cancer Detect Prev; 1998; 22(4):313-8. PubMed ID: 9674874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
